Phytopharm's Cogane to be evaluated in Huntington's disease
This article was originally published in Scrip
Executive Summary
Phytopharm has entered an agreement with CHDI Foundation to evaluate the efficacy of its non-peptide, orallyactive, neurotrophic factor inducer PYM50028 (Cogane) in a preclinical model of Huntington's disease.